Clinical Trial Detail

NCT ID NCT03037385
Title Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Blueprint Medicines Corporation
Indications

Advanced Solid Tumor

thyroid gland medullary carcinoma

lung non-small cell carcinoma

Therapies

Pralsetinib

Age Groups: adult senior

Additional content available in CKB BOOST